Cytokinetics forges $75M financing deal

South San Francisco-based Cytokinetics has forged a new deal with Kingsbridge Capital Limited that will provide up to $75 million in fresh financing over the next three years. In the deal, Kingsbridge commits to buying newly issued shares of Cytokinetics stock. Cytokinetics has a couple of high profile deals working with Amgen and GlaxoSmithKline and has an intriguing small molecule candidate in Phase II for heart failure.

"This is a secondary source of capital," says Cytokinetics CEO Robert Blum in an interview. And it's the second deal the company has made with Kingsbridge, which specializes in this kind of arrangement. "We gain access to capital in a metered way as we need it to keep our balance sheet shored up. This type of tool was not available a couple of years ago." And its much better than alternative types of financing, he adds, which include "more toxic provisions."

- see the company release on the funding

Related Articles:
Cytokinetics drug fails in three cancer indications. Report
Cytokinetics' drug flunks another cancer trial. Report
Cytokinetics assumes responsibility in amended pact. Report

Read more on: Cytokinetics

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.